Vaccination prevents severe COVID-19 outcome in patients with neutralizing type 1 interferon autoantibodies
© 2023 The Author(s)..
A hallmark of patients with autoimmune polyendocrine syndrome type 1 (APS-1) is serological neutralizing autoantibodies against type 1 interferons (IFN-I). The presence of these antibodies has been associated with severe course of COVID-19. The aims of this study were to investigate SARS-CoV-2 vaccine tolerability and immune responses in a large cohort of patients with APS-1 (N = 33) and how these vaccinated patients coped with subsequent infections. We report that adult patients with APS-1 were able to mount adequate SARS-CoV-2 spike-specific antibody responses after vaccination and observed no signs of decreased tolerability. Compared with age- and gender-matched healthy controls, patients with APS-1 had considerably lower peak antibody responses resembling elderly persons, but antibody decline was more rapid in the elderly. We demonstrate that vaccination protected patients with APS-1 from severe illness when infected with SARS-CoV-2 virus, overriding the systemic danger of IFN-I autoantibodies observed in previous studies.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:26 |
|---|---|
| Enthalten in: |
iScience - 26(2023), 7 vom: 21. Juli, Seite 107084 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Wolff, Anette S B [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Biological sciences |
|---|
| Anmerkungen: |
Date Revised 01.07.2023 published: Print-Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1016/j.isci.2023.107084 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM358474841 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM358474841 | ||
| 003 | DE-627 | ||
| 005 | 20231226074823.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.isci.2023.107084 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1194.xml |
| 035 | |a (DE-627)NLM358474841 | ||
| 035 | |a (NLM)37346050 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Wolff, Anette S B |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Vaccination prevents severe COVID-19 outcome in patients with neutralizing type 1 interferon autoantibodies |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 01.07.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © 2023 The Author(s). | ||
| 520 | |a A hallmark of patients with autoimmune polyendocrine syndrome type 1 (APS-1) is serological neutralizing autoantibodies against type 1 interferons (IFN-I). The presence of these antibodies has been associated with severe course of COVID-19. The aims of this study were to investigate SARS-CoV-2 vaccine tolerability and immune responses in a large cohort of patients with APS-1 (N = 33) and how these vaccinated patients coped with subsequent infections. We report that adult patients with APS-1 were able to mount adequate SARS-CoV-2 spike-specific antibody responses after vaccination and observed no signs of decreased tolerability. Compared with age- and gender-matched healthy controls, patients with APS-1 had considerably lower peak antibody responses resembling elderly persons, but antibody decline was more rapid in the elderly. We demonstrate that vaccination protected patients with APS-1 from severe illness when infected with SARS-CoV-2 virus, overriding the systemic danger of IFN-I autoantibodies observed in previous studies | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Biological sciences | |
| 650 | 4 | |a Health sciences | |
| 650 | 4 | |a Immune response | |
| 650 | 4 | |a Immunology | |
| 700 | 1 | |a Hansen, Lena |e verfasserin |4 aut | |
| 700 | 1 | |a Grytaas, Marianne Aa |e verfasserin |4 aut | |
| 700 | 1 | |a Oftedal, Bergithe E |e verfasserin |4 aut | |
| 700 | 1 | |a Breivik, Lars |e verfasserin |4 aut | |
| 700 | 1 | |a Zhou, Fan |e verfasserin |4 aut | |
| 700 | 1 | |a Hufthammer, Karl Ove |e verfasserin |4 aut | |
| 700 | 1 | |a Sjøgren, Thea |e verfasserin |4 aut | |
| 700 | 1 | |a Olofsson, Jan Stefan |e verfasserin |4 aut | |
| 700 | 1 | |a Trieu, Mai Chi |e verfasserin |4 aut | |
| 700 | 1 | |a Meager, Anthony |e verfasserin |4 aut | |
| 700 | 1 | |a Jørgensen, Anders P |e verfasserin |4 aut | |
| 700 | 1 | |a Lima, Kari |e verfasserin |4 aut | |
| 700 | 1 | |a Greve-Isdahl Mohn, Kristin |e verfasserin |4 aut | |
| 700 | 1 | |a Langeland, Nina |e verfasserin |4 aut | |
| 700 | 1 | |a Cox, Rebecca Jane |e verfasserin |4 aut | |
| 700 | 1 | |a Husebye, Eystein S |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t iScience |d 2018 |g 26(2023), 7 vom: 21. Juli, Seite 107084 |w (DE-627)NLM285332627 |x 2589-0042 |7 nnns |
| 773 | 1 | 8 | |g volume:26 |g year:2023 |g number:7 |g day:21 |g month:07 |g pages:107084 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.isci.2023.107084 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 26 |j 2023 |e 7 |b 21 |c 07 |h 107084 | ||